Overview
- A literature review led by David C. Rubinsztein consolidates preclinical evidence that leucine‑derived acetyl‑coenzyme A (AcCoA) activates the acetyltransferase p300, which acetylates Raptor and promotes mTORC1 signaling in neurons and glia.
- The review argues chronic mTORC1 hyperactivation from this AcCoA–p300–Raptor axis suppresses autophagy, which can drive toxic protein buildup seen in Alzheimer’s, Parkinson’s, Huntington’s and ALS models.
- Authors caution that much of past mTORC1 biology was built on HEK293 cell experiments and that neuronal nutrient sensing may use different mechanisms, creating a need to study neuron‑specific pathways directly.
- Instead of directly blocking mTORC1, the review proposes upstream interventions such as lowering neuronal AcCoA production, inhibiting p300 acetylation activity, or interrupting inflammatory crosstalk (for example CCR5 signaling) as translational strategies.
- The synthesis is based on preclinical studies and is presented as a developing hypothesis; the review notes model limitations, ongoing evidence gaps, and declares industry consultancies by the lead author, so clinical therapies targeting this axis are not yet validated.